Neuroprotective therapeutic strategies. Comparison of experimental and clinical results.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Biochemical Pharmacology

• Publication date

  1995-06-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0006-2952(95)00051-ZPMID 7605334
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Competitive and noncompetitive N-methyl-D-aspartate antagonists protect dopaminergic and serotonergic neurotoxicity produced by methamphetamine in various brain regions

  2005cited by this paper
• Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain

  2005cited by this paper
• Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff's disease

  2004cited by this paper
• Oxidative stress: Free radical production in neural degeneration

  1994cited by this paper
• A controlled trial of lazabemide (Ro 19-6327) in levodopa-treated Parkinson's disease

  1994cited by this paper
• Altered Brain Metabolism of Iron as a Cause of Neurodegenerative Diseases?

  1994cited by this paper
• Nitric oxide: A radical neurotransmitter in the central nervous system

  1994cited by this paper
• Rapid Communication: Cu/Zn Superoxide Dismutase Activity in Familial and Sporadic Amyotrophic Lateral Sclerosis

  1994cited by this paper
• Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide

  1994cited by this paper
• A controlled trial of lazabemide (Ro 19-6327) in levodopa-treated Parkinson's disease. Parkinson Study Group.

  1994cited by this paper
• Glutamate-evoked release of arachidonic acid from mouse brain astrocytes

  1994cited by this paper
• Oxidative stress: free radical production in neural degeneration.

  1994cited by this paper
• Nitric oxide: a downstream mediator of calcium toxicity in the ischemic cascade

  1994cited by this paper
• Effect of 21-aminosteroid lipid peroxidation inhibitor, U74006F, in the rat middle cerebral artery occlusion model.

  1994cited by this paper
• Towards an understanding of the role of glutamate in neurodegenerative disorders: energy metabolism and neuropathology

  1993cited by this paper
• The neurotoxicity of iron and nitric oxide. Relevance to the etiology of Parkinson's disease.

  1993cited by this paper
• Congruity of acetylcholine receptor, acetylcholinesterase, and Dolichos biflorus lectin binding glycoprotein in postsynaptic‐like sarcolemmal specializations in noninnervated regenerating rat muscles

  1993cited by this paper
• Brain calcium channel related dihydropyridine and phenylalkylamine binding sites in Alzheimer's, Parkinson's and Huntington's diseases.

  1993cited by this paper
• Effect of KB-2796, a new diphenylpiperazine Ca2+ antagonist, on glutamate-induced neurotoxicity in rat hippocampal primary cell cultures.

  1993cited by this paper
• The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.

  1993cited by this paper
• Mechanisms of neurotrophic factor protection against calcium- and free radical-mediated excitotoxic injury: implications for treating neurodegenerative disorders.

  1993cited by this paper
• The dihydropyridine nitrendipine modulates N-methyl-D-aspartate receptor channel function in mammalian neurons.

  1993cited by this paper
• Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease.

  1993cited by this paper
• Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis.

  1993cited by this paper
• A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

  1993cited by this paper
• Infusion of iron into the rat substantia nigra: Nigral pathology and dose‐dependent loss of striatal dopaminergic markers

  1993cited by this paper
• MPP+ and MPDP+ induced oxygen radical formation with mitochondrial enzymes.

  1993cited by this paper
• Parkinson's disease and the electron transport chain in postmortem brain.

  1993cited by this paper
• The Pathophysiological Basis of Parkinson’s Disease

  1993cited by this paper
• Inhibitors of monoamine oxidase B

  1993cited by this paper
• Do defecs in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases

  1993cited by this paper
• A radical hypothesis for neurodegeneration.

  1993cited by this paper
• Oxidative stress, glutamate, and neurodegenerative disorders.

  1993cited by this paper
• Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity

  1993cited by this paper
• Presymptomatic detection of Parkinson's disease.

  1993cited by this paper
• Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis

  1993cited by this paper
• Role of dopamine autoxidation, hydroxyl radical generation, and calcium overload in underlying mechanisms involved in MPTP-induced parkinsonism.

  1993cited by this paper
• Reduction of calbindin-28k mRNA levels in Alzheimer as compared to Huntington hippocampus.

  1993cited by this paper
• The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it

  1992cited by this paper
• Recovery from experimental parkinsonism in primates with GM1 ganglioside treatment.

  1992cited by this paper
• A novel neuronal messenger molecule in brain: The free radical, nitric oxide

  1992cited by this paper
• Neurotoxicity and neuroprotection in Parkinson's disease.

  1992cited by this paper
• MRI, brain iron and experimental Parkinson's disease.

  1992cited by this paper
• Cigarette smoking and Parkinson disease: the illusion of a neuroprotective effect.

  1992cited by this paper
• Changes in Ca(2+)-binding proteins in human neurodegenerative disorders.

  1992cited by this paper
• Extracellular superoxide dismutase, nitric oxide, and central nervous system O2 toxicity.

  1992cited by this paper
• Vitamin E attenuates the toxic effects of 6-hydroxydopamine on free radical scavenging systems in rat brain.

  1992cited by this paper
• Irreversible Inhibition of Mitochondrial Complex I by 1‐Methyl‐4‐Phenylpyridinium: Evidence for Free Radical Involvement

  1992cited by this paper
• Dihydrolipoate Reduces Neuronal Injury after Cerebral Ischemia

  1992cited by this paper
• The molecular pharmacology of L-deprenyl.

  1992cited by this paper
• Iron induces degeneration of nigrostriatal neurons.

  1992cited by this paper
• Nitric oxide takes centre-stage with newly defined roles.

  1992cited by this paper
• Neuroprotective Effects of L-Kynurenine on Hypoxia—Ischemia and NMDA Lesions in Neonatal Rats

  1992cited by this paper
• Reactive Oxygen Species and the Central Nervous System

  1992cited by this paper
• Superoxide dismutases.

  1991cited by this paper
• Iron‐Melanin Interaction and Lipid Peroxidation: Implications for Parkinson's Disease

  1991cited by this paper
• Oxidative stress as a cause of Parkinson's disease

  1991cited by this paper
• Cytotoxic Effect of Brain Macrophages on Developing Neurons

  1991cited by this paper
• Aminooxyacetic Acid Results in Excitotoxin Lesions by a Novel Indirect Mechanism

  1991cited by this paper
• MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease.

  1991cited by this paper
• Regional brain and cerebrospinal fluid quinolinic acid concentrations in Huntington's disease.

  1991cited by this paper
• Partial purification and characterization of a Ca2+/calmodulin-dependent endothelium-derived relaxing factor-forming enzyme from porcine cerebellum

  1991cited by this paper
• The Iron Chelator Desferrioxamine (Desferal) Retards 6‐Hydroxydopamine‐Induced Degeneration of Nigrostriatal Dopamine Neurons

  1991cited by this paper
• Early Markers in Parkinson’s and Alzheimer’s Diseases

  1991cited by this paper
• Memantine is highly potent in protecting cortical cultures against excitotoxic cell death evoked by glutamate and N-methyl-D-aspartate.

  1991cited by this paper
• Intranigral Iron Injection Induces Behavioral and Biochemical “Parkinsonism” in Rats

  1991cited by this paper
• Chronic quinolinic acid lesions in rats closely resemble Huntington's disease

  1991cited by this paper
• Phosphate/calcium alterations in the first stages of Alzheimer's disease: implications for etiology and pathogenesis.

  1991cited by this paper
• Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway.

  1991cited by this paper
• Positron emission tomography suggests that the rate of progression of idiopathic parkinsonism is slow

  1991cited by this paper
• Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide.

  1991cited by this paper
• Cytoprotective function of nitric oxide: inactivation of superoxide radicals produced by human leukocytes.

  1991cited by this paper
• Parkinson's disease: an epidemiologic method for distinguishing between symptomatic and neuroprotective treatments.

  1991cited by this paper
• Can we differentiate symptomatic and neuroprotective effects in parkinsonism? The dopamine agonist lisuride delays the need for levodopa therapy to a similar extent as reported for deprenyl.

  1991cited by this paper
• [3H]nitrendipine binding in temporal cortex in Alzheimer's and Huntington's diseases.

  1991cited by this paper
• Purification and characterization of a human NO synthase.

  1991cited by this paper
• Parvalbumin Neurons in the Hippocampus in Senile Dementia of the Alzheimer Type, Parkinson's Disease and Multi-Infarct Dementia (Part 1 of 2)

  1991cited by this paper
• Excitatory amino acid neurotoxicity and neurodegenerative disease.

  1990cited by this paper
• The quinolinic acid hypothesis in Huntington's chorea.

  1990cited by this paper
• Excitatory amino acid receptors, second messengers and regulation of intracellular Ca2+ in mammalian neurons.

  1990cited by this paper
• Specific reduction of calcium-binding protein (28-kilodalton calbindin-D) gene expression in aging and neurodegenerative diseases.

  1990cited by this paper
• GM1 gangliosides alter acute MPTP-induced behavioral and neurochemical toxicity in mice.

  1990cited by this paper
• Nitric oxide mediates iron release from ferritin.

  1990cited by this paper
• Calcium in the brain under physiological and pathological conditions.

  1990cited by this paper
• Neurotoxic action of veratridine in rat brain neuronal cultures: mechanism of neuroprotection by Ca++ antagonists nonselective for slow Ca++ channels.

  1990cited by this paper
• Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme.

  1990cited by this paper
• Brain iron and ferritin in Parkinson's and Alzheimer's diseases

  1990cited by this paper
• Inhibition by nitric oxide and nitric oxide-producing vasodilators of DNA synthesis in vascular smooth muscle cells.

  1990cited by this paper
• Secretion of neurotoxins by mononuclear phagocytes infected with HIV-1

  1990cited by this paper
• Neuroprotective effect of memantine demonstrated in vivo and in vitro.

  1990cited by this paper
• Localization of nitric oxide synthase indicating a neural role for nitric oxide

  1990cited by this paper
• 1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles.

  1990cited by this paper
• Differential diagnosis of Parkinson’s disease

  1990cited by this paper
• Early markers in Parkinson’s disease

  1990cited by this paper
• Neurotoxicity of excitatory amino acids

  1990cited by this paper
• EPR demonstration of iron-nitrosyl complex formation by cytotoxic activated macrophages.

  1990cited by this paper
• Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide.

  1990cited by this paper
• The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.

  1989cited by this paper
• Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity.

  1989cited by this paper
• 6-Hydroxydopamine releases iron from ferritin and promotes ferritin-dependent lipid peroxidation.

  1989cited by this paper

• Ligands for the dopamine D 2-like receptors

  2017cites this paper
• Neurologic Disorders in Children with Heart Disease

  2012cites this paper
• Strategies for the protection of dopaminergic neurons against neurotoxicity

  2009cites this paper
• Biomarkers for Early Detection of Parkinson's Disease: An Essential Challenge

  2008cites this paper
• Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study

  2005cites this paper
• Behavioral and antioxidant activity of a tosylbenz[g]indolamine derivative. A proposed better profile for a potential antipsychotic agent

  2004cites this paper
• Advances in neuroprotection research for neurodegenerative diseases.

  2004cites this paper
• Arguments for the use of dopamine receptor agonists in clinical and preclinical Parkinson's disease.

  2003cites this paper
• Selegiline’s neuroprotective capacity revisited

  2003cites this paper
• Preclinical versus clinical neuroprotection.

  2003cites this paper
• Selegiline's neuroprotective capacity revisited Commentary

  2003cites this paper
• Role of spin trapping and P2Y receptor antagonism in the neuroprotective effects of 2,2'-pyridylisatogen tosylate and related compounds.

  2002cites this paper
• Effects of S-adenosyl-L-methionine on lipid peroxidation and glutathione levels in rat brain slices exposed to reoxygenation after oxygen-glucose deprivation.

  2002cites this paper
• A Serum- and Antioxidant-Free Primary Culture Model of Mouse Cortical Neurons for Pharmacological Screen and Studies of Neurotrophic and Neuroprotective Agents

  2002cites this paper
• Outcomes - Based Practice

  2001cites this paper
• Inhibitory effect of fangchinoline on excitatory amino acids-induced neurotoxicity in cultured rat cerebellar granule cells

  2001cites this paper
• The neuroprotective activity of 8-alkylamino-1,4-benzoxazine antioxidants.

  2001cites this paper
• Effect of S-adenosyl-L-methionine on rat brain oxidative stress damage in a combined model of permanent focal ischemia and global ischemia-reperfusion.

  2000cites this paper
• New, centrally acting dopaminergic agents with an improved oral bioavailability: synthesis and pharmacological evaluation

  2000cites this paper
• An Evidence-Based Approach to Management of Early Parkinson ’ s Disease

  2000cites this paper
• Potential Role of Cannabinoids in Parkinson’s Disease

  2000cites this paper
• Neuroprotective action of a novel compound--M50463--in primary cultured neurons.

  1999cites this paper
• Therapie von oxidativem Streß

  1999cites this paper
• Pathophysiologische Grundlagen und Prinzipien der Pharmakotherapie

  1999cites this paper
• Intracerebroventricular administration of substance P increases dopamine content in the brain of 6-hydroxydopamine-lesioned rats.

  1999cites this paper
• Neuroprotective action of a novel compound-M50463-in primary cultured neurons

  1999cites this paper
• Nitric oxide‐containing neurons in the nervous ganglia of Helix aspersa during rest and activity: Immunocytochemical and enzyme histochemical detection

  1999cites this paper
• Ligands for the dopamine D2-like receptors

  1998cites this paper
• Simple and choice reaction-time performance following occlusion of the anterior cerebral arteries in the rat

  1998cites this paper
• Antioxidant properties of the triaminopyridine, flupirtine.

  1998cites this paper
• Experimental Models of Parkinson's Disease: From the Static to the Dynamic

  1998cites this paper
• Effect of propofol on oxidative stress in an in vitro model of anoxia-reoxygenation in the rat brain.

  1998cites this paper
• Culture medium components modulate retina cell damage induced by glutamate, kainate or "chemical ischemia".

  1998cites this paper
• Free-radical toxicity and antioxidant medications in Parkinson's disease.

  1998cites this paper
• Selegiline as immunostimulant--a novel mechanism of action?

  1998cites this paper
• Free radicals in Alzheimer's dementia: currently available therapeutic strategies.

  1998cites this paper
• Effects of aloin and some structure-related anthracene, anthracenone, and anthraquinone derivatives on lipid peroxidation in rat brain cortex homogenates.

  1997cites this paper
• A role of nitric oxide in organophosphate-induced convulsions.

  1997cites this paper
• N-methyl-D-aspartate antagonists for stroke and head trauma.

  1997cites this paper
• Assessment of sensorimotor neglect after occlusion of the middle cerebral artery in the rat.

  1997cites this paper
• Anti-oxidant therapy: does it have a role in the treatment of human disease?

  1997cites this paper
• Oxidative stress and the pathogenesis of Parkinson's disease

  1996cites this paper
• Characterization of drugs as antioxidant prophylactics.

  1996cites this paper
• Selegiline stimulates biosynthesis of cytokines interleukin-1 beta and interleukin-6.

  1996cites this paper
• Early Diagnosis of Parkinson’s Disease in New Neurological Patients by Testing of Visuo-Manual Coordination

  1996cites this paper
• Pharmacokinetic Optimisation in the Treatment of Parkinson’s Disease

  1996cites this paper
• Effect of intracellular iron loading on lipid peroxidation of brain slices.

  1996cites this paper
• Interaction of 1,4-dihydropyridine and pyridine derivatives with adenosine receptors: selectivity for A3 receptors.

  1996cites this paper